Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record.

Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

Open access
Gnjatic, Sacha, Atanackovic, Djordje, Jäger, Elke, Matsuo, Mitsutoshi, Selvakumar, Annamalai, Altorki, Nasser K., Maki, Robert G., Dupont, Bo, Ritter, Gerd, Chen, Yao-Tseng, Knuth, Alexander, Old, Lloyd J.·2003·Proceedings of the National Academy of Sciences

Abstract

NY-ESO-1 is one of the most immunogenic proteins described in human cancers, based on its capacity to elicit simultaneous antibody and CD8 + T cell responses in vivo . Although HLA class II restricted epitopes from NY-ESO-1 have been identified, no broad survey has yet established the status of natural CD4 + T cell responses in cancer patients in relation to CD8 + and antibody responses. We used a recently developed general strategy for monitoring CD4 + responses that overcomes the need for prior knowledge of epitope or HLA restriction to analyze a series of 31 cancer patients and healthy donors for the presence of CD4 + T cells to NY-ESO-1, and related this response to NY-ESO-1 expression in tumor cells and serum antibodies to NY-ESO-1. None of the 18 patients that tested seronegative for NY-ESO-1 had detectable CD4 + T cell responses. On the contrary, 11 of 13 cancer patients with serum antibodies to NY-ESO-1 had polyclonal CD4 + T cell responses directed against various known and previously undescribed NY-ESO-1 epitopes. NY-ESO-1 peptide 80–109 was the most immunogenic, with 10 of 11 patients responding to this peptide. We show here that 12-mer determinants from NY-ESO-1 eliciting a CD4 + T cell response were peptide 87–98 with promiscuous HLA class II presentation, peptide 108–119 restricted by HLA-DP4, and peptides 121–132 and 145–156, both shorter epitopes from previously described HLA-DR4 peptides, also presented by HLA-DR7. This study represents the next step in compiling a comprehensive picture of the adaptive immune response to NY-ESO-1, and provides a general strategy for analyzing the CD4 + T cell response to other tumor antigens eliciting a humoral immune response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1133324100

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 203

Metadata

Authors
Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G., Dupont, B., Ritter, G., Chen, Y.-T., Knuth, A., & Old, L. J.
Venue
Proceedings of the National Academy of Sciences
Published
2003-07-09
Volume
100
Issue
15
Pages
8862-8867
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2030317951
Cited by
203
References
0
FWCI
6.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. https://app.cochat.ai/papers/10.1073/pnas.1133324100
The paper
Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G., Dupont, B., Ritter, G., Chen, Y.-T., Knuth, A., & Old, L. J. (2003). Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1133324100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.